When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.


Last reviewed: 5 Sep 2023
Last updated: 19 Oct 2021



History and exam

Key diagnostic factors

  • coarsening of facial features
  • soft-tissue and skin changes
  • carpal tunnel syndrome
  • joint pain and dysfunction
  • snoring
  • alterations in sexual functioning
  • history or family history of inherited syndrome
More key diagnostic factors

Other diagnostic factors

  • fatigue
  • hypertension, arrhythmias
  • organomegaly
  • increased appetite, polyuria/polydipsia
  • headaches
  • visual field defects
  • signs and symptoms of hypopituitarism
  • cranial nerve palsies (e.g., ophthalmoplegia)
Other diagnostic factors

Risk factors

  • GPR101 overexpression
  • multiple endocrine neoplasia type 1 syndrome
  • isolated familial acromegaly
  • McCune-Albright syndrome
  • Carney complex
More risk factors

Diagnostic investigations

1st investigations to order

  • serum insulin-like growth factor 1 (IGF-1)
  • oral glucose tolerance test (OGTT)
  • random serum growth hormone (GH)
More 1st investigations to order

Investigations to consider

  • pituitary MRI or CT scan
  • GH-releasing hormone
  • chest and/or abdominal CT scanning
  • total body scintigraphy with radiolabeled somatostatin analog (octreoscan)
  • PET scan with radiolabeled somatostatin analog (Gallium-68 DOTATATE)
  • plasma cortisol
  • prolactin
  • thyroid-stimulating hormone (TSH) and free thyroxine
  • estradiol or testosterone
  • visual field testing
More investigations to consider

Treatment algorithm


enclosed pituitary tumor

unresectable pituitary tumor (with neural or vascular impingement/invasion)

nonpituitary adenoma etiology


pituitary adenoma progression or recurrence



Maria Fleseriu, MD, FACE

Professor of Medicine (Endocrinology) and Neurological Surgery


Pituitary Center

Oregon Health & Science University




MF declares that she receives research funding (paid to Oregon Health & Science University) as well as scientific consulting fees from Chiasma, Crinetics, Ionis and Recordati; she receives scientific consulting fees from Ipsen and Pfizer. MF is an author of a number of references cited in this topic.


Professor Fleseriu would like to gratefully acknowledge Professor Ariel Barkan, Dr Omar Serri and Dr Sophie Vallette, previous contributors to this topic.


AB has received lecturing fees and research support from Novartis and Ipsen and is an author of several references cited in this topic. OS has received lecturing and educational program fees from Novartis Canada and is an author of a reference cited in this topic. SV has received fees for lecturing and attending a symposium and is an author of a reference cited in this topic.

Peer reviewers

Robert D. Murray, MBBS, BSc, FRCP, MD

Consultant Endocrinologist & Honorary Senior Lecturer

Department of Endocrinology

Leeds Centre for Diabetes & Endocrinology

Leeds Teaching Hospitals NHS Trust

St James’s University Hospital




RDM declares that he has no competing interests.

Shlomo Melmed, MD

Senior Vice President and Dean

Cedars Sinai Medical Center

Los Angeles



SM has research grants of over 6 figures USD. SM is an author of a number of references cited in this topic.

Laurence Kennedy, MD, FRCP

Professor and Chief


Department of Endocrinology, Diabetes and Metabolism

Cleveland Clinic




LK declares that he has no competing interests.

  • Acromegaly images
  • Differentials

    • acromegaloidism or pseudoacromegaly
    More Differentials
  • Guidelines

    • A Pituitary Society update to acromegaly management guidelines
    • A consensus on the diagnosis and treatment of acromegaly comorbidities: an update
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer